Results 141 to 150 of about 9,620 (164)

Canakinumab

Reactions Weekly, 2017
  +4 more sources

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever

Rheumatology, 2023
Emil Aliyev, Yelda Bilginer
exaly  

Canakinumab for Secondary Prevention of Coronary Artery Disease

Future Cardiology, 2021
Dominick Angiolillo, , Luis Ortega-Paz
exaly  

Canakinumab

Reactions Weekly, 2023
openaire   +1 more source

Canakinumab

Reactions Weekly, 2018
openaire   +2 more sources

<p>The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature</p>

Journal of Inflammation Research, 2020
Siniša Savic, Mark Kačar, Jeroen Van Der Hilst   +2 more
exaly  

The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet’s Disease

Ocular Immunology and Inflammation, 2020
Donato Rigante, Gian Marco Tôsi, Giacomo Emmi   +2 more
exaly  

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Lancet, The, 2017
Marcus Flather, Prem Pais, Tom Thurén   +2 more
exaly  

Canakinumab for secondary prevention of atherosclerotic disease

Expert Opinion on Biological Therapy, 2018
Dominick Angiolillo
exaly  

The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective

International Journal of Cardiology, 2019
, Danny Yearn Hian Liew, Zanfina Ademi
exaly